array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2445)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(62) "Kukje Pharma to sell Celltion’s Eylea biosimilar exclusively"
["snippet_en"]=>
string(300) "Kukje Pharma said Tuesday that it has signed a strategic marketing partnership contract with Celltrion for the domestic sales of Celltrion's CT-P42 (aflibercept), an Eylea biosimilar, for treating ophthalmic retinal diseases.Under the agreement, Celltrion will exclusively provide Kukje Pharma with d"
["url"]=>
string(61) "https://www.koreabiomed.com/news/articleView.html?idxno=23727"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ac3bc19e-c756-4d94-8464-57e09ecab462"
["source"]=>
string(15) "koreabiomed.com"
["publication_date"]=>
string(10) "2024-04-02"
["categories"]=>
array(1) {
[0]=>
string(13) "Collaboration"
}
}
[1]=>
array(7) {
["title_en"]=>
string(116) "Adium announces an exclusive distribution agreement with Regeneron for the commercialization of Cemiplimab in Brazil"
["snippet_en"]=>
string(148) "Pharmaceutical company Adium announces exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron, for Libt"
["url"]=>
string(136) "https://saludnews.net/adium-anuncia-un-acuerdo-de-distribucion-exclusiva-con-regeneron-para-la-comercializacion-de-cemiplimab-en-brasil/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/f9806725-d463-475f-baf3-e64255bac539"
["source"]=>
string(13) "saludnews.net"
["publication_date"]=>
string(10) "2024-03-30"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(15) "Deals & Tenders"
}
}
[2]=>
array(7) {
["title_en"]=>
string(112) "2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron | TSVT Stock News"
["snippet_en"]=>
string(229) "2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma."
["url"]=>
string(115) "https://www.stocktitan.net/news/TSVT/2seventy-bio-announces-completion-of-oncology-and-autoimmune-65ex5m9fekls.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/dd4bdefa-472d-41a7-9009-ab29959775ab"
["source"]=>
string(14) "stocktitan.net"
["publication_date"]=>
string(10) "2024-03-20"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(15) "Deals & Tenders"
}
}
[3]=>
array(7) {
["title_en"]=>
string(125) "Empowering Future Scientists: Hudson County's Annual STEM Showcase Celebrates Creativity and Technical Skills - News Chemical"
["snippet_en"]=>
string(155) "The annual Hudson County STEM Showcase, hosted by Jersey City Medical Center in partnership with Liberty Science Center, took place on March 11. This event"
["url"]=>
string(133) "https://newschemical.com/empowering-future-scientists-hudson-countys-annual-stem-showcase-celebrates-creativity-and-technical-skills/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/7207bc88-5215-4999-b7dc-f6b641397771"
["source"]=>
string(16) "newschemical.com"
["publication_date"]=>
string(10) "2024-03-16"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(5) "Event"
}
}
[4]=>
array(7) {
["title_en"]=>
string(76) "Partnership makes new cancer drug viable in Brazil | Pharmaceutical Panorama"
["snippet_en"]=>
string(116) "A new cancer drug will become available in Brazil through a partnership between Adium and Regeneron. By agreement..."
["url"]=>
string(71) "https://panoramafarmaceutico.com.br/medicamento-contra-o-cancer-brasil/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/78cdad45-5375-4ad8-b474-3413476e8b34"
["source"]=>
string(27) "panoramafarmaceutico.com.br"
["publication_date"]=>
string(10) "2024-03-15"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(14) "Product Launch"
}
}
[5]=>
array(7) {
["title_en"]=>
string(30) "GENESIS-PHARMA | Business Wire"
["snippet_en"]=>
string(147) "GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta"
["url"]=>
string(88) "https://via.ritzau.dk/pressemeddelelse/13787386/genesis-pharma?publisherId=90456&lang=en"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/da91a8de-3b23-4b5e-a877-b5a3d333fcec"
["source"]=>
string(9) "ritzau.dk"
["publication_date"]=>
string(10) "2024-03-01"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(15) "Deals & Tenders"
}
}
[6]=>
array(7) {
["title_en"]=>
string(128) "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries"
["snippet_en"]=>
string(158) "/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international..."
["url"]=>
string(182) "https://www.prnewswire.co.uk/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a5536b51-142d-4a07-8c9b-f46a94f9b2c2"
["source"]=>
string(16) "prnewswire.co.uk"
["publication_date"]=>
string(10) "2024-01-08"
["categories"]=>
array(3) {
[0]=>
string(13) "Collaboration"
[1]=>
string(24) "Access and affordability"
[2]=>
string(15) "Deals & Tenders"
}
}
[7]=>
array(7) {
["title_en"]=>
string(92) "Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics - Pharmafile"
["snippet_en"]=>
string(152) "Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a collaboration agreement for the development and"
["url"]=>
string(108) "https://pharmafile.com/news/owkin-and-merck-enter-collaboration-agreement-for-ai-powered-cancer-diagnostics/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b3f9ee16-32cd-4ef4-b2e9-1c564440eea6"
["source"]=>
string(14) "pharmafile.com"
["publication_date"]=>
string(10) "2023-12-20"
["categories"]=>
array(1) {
[0]=>
string(13) "Collaboration"
}
}
[8]=>
array(7) {
["title_en"]=>
string(127) "Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart"
["snippet_en"]=>
string(292) "NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited( `` Simcere '') entered into an exclusive license and collaboration agreement( the `` Agreement '') with Connect Biopharma HongKong Limited( `` Connect '') in relation to Rademikibart, an"
["url"]=>
string(115) "https://www.asiaone.com/business/simcere-and-connect-enter-exclusive-license-and-collaboration-agreement-innovative"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b06846e9-9b6c-4224-878b-e7007bb6808c"
["source"]=>
string(11) "asiaone.com"
["publication_date"]=>
string(10) "2023-11-23"
["categories"]=>
array(5) {
[0]=>
string(13) "Collaboration"
[1]=>
string(11) "Competition"
[2]=>
string(37) "Product Design & Lifecycle Management"
[3]=>
string(15) "Market Movement"
[4]=>
string(14) "Product Launch"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(101)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(30)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2445 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Kukje Pharma said Tuesday that it has signed a strategic marketing partnership contract with Celltrion for the domestic sales of Celltrion's CT-P42 (aflibercept), an Eylea biosimilar, for treating ophthalmic retinal diseases.Under the agreement, Celltrion will exclusively provide Kukje Pharma with d
2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma.
The annual Hudson County STEM Showcase, hosted by Jersey City Medical Center in partnership with Liberty Science Center, took place on March 11. This event
/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international...
Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a collaboration agreement for the development and
NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited( `` Simcere '') entered into an exclusive license and collaboration agreement( the `` Agreement '') with Connect Biopharma HongKong Limited( `` Connect '') in relation to Rademikibart, an
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
